Literature DB >> 8387225

A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies.

S Hildebrandt1, G Jäckh, S Weber, H H Peter.   

Abstract

In this first retrospective longitudinal study of anti-topoisomerase I autoantibodies (anti-topo I) we examined the isotypic expression in 13 patients with scleroderma by enzyme-linked immunosorbent assay. Titers were stable for up to 16 years. However, one patient lost the antibody, while another developed high levels of IgM with myositis and another, high levels of IgA with cardiac disease. For the first time the de novo development of anti-topo I was observed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8387225     DOI： 10.1007/bf00301007

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  11 in total

1.  Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay.

Authors:  S Hildebrandt; E S Weiner; J L Senecal; G S Noell; W C Earnshaw; N F Rothfield
Journal:  Clin Immunol Immunopathol       Date:  1990-12

2.  Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus.

Authors:  G J Tsay; R H Fann; J Hwang
Journal:  J Rheumatol       Date:  1990-10       Impact factor: 4.666

3.  The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies.

Authors:  S Hildebrandt; E Weiner; J L Senécal; S Noell; L Daniels; W C Earnshaw; N F Rothfield
Journal:  Arthritis Rheum       Date:  1990-05

4.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

5.  Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.

Authors:  E S Weiner; W C Earnshaw; J L Senécal; B Bordwell; P Johnson; N F Rothfield
Journal:  Arthritis Rheum       Date:  1988-03

6.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

7.  High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients.

Authors:  J H Shero; B Bordwell; N F Rothfield; W C Earnshaw
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study.

Authors:  E S Weiner; S Hildebrandt; J L Senécal; L Daniels; S Noell; F Joyal; A Roussin; W Earnshaw; N F Rothfield
Journal:  Arthritis Rheum       Date:  1991-01

10.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06
View more
  5 in total

1.  Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.

Authors:  D Villalta; N Bizzaro; S Platzgummer; A Antico; M Tampoia; L Camogliano; D Bassetti; M Pradella; A Piazza; F Manoni; R Tozzoli; E Tonutti
Journal:  Clin Rheumatol       Date:  2004-12-10       Impact factor: 2.980

2.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling.

Authors:  Jennifer L Sargent; Michael L Whitfield
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

4.  Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes.

Authors:  Kristina E N Clark; Corrado Campochiaro; Lauren V Host; Alper Sari; Jennifer Harvey; Christopher P Denton; Voon H Ong
Journal:  Sci Rep       Date:  2022-07-02       Impact factor: 4.996

5.  Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.

Authors:  Maaike Boonstra; Jaap A Bakker; Annette Grummels; Maarten K Ninaber; Nina Ajmone Marsan; Corrie M Wortel; Tom W J Huizinga; Suzana Jordan; Anna-Maria Hoffman-Vold; Oliver Distler; René E M Toes; Hans Ulrich Scherer; Jeska K de Vries-Bouwstra
Journal:  Arthritis Rheumatol       Date:  2020-09-29       Impact factor: 10.995
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.